Price capping for prescription drugs in America based on International Reference Pricing demonstrated high magnitude of savings.
Linking the cost of prescription drugs in the United States to the prices paid in other high-income nations con reduce the burden of Americans spending for the drugs by at least half in 2020, according to a new RAND Corporation study. Researchers found that such a move would have cut U.S. spending on insulins and 50 top brand-name drugs by 52% during 2020 – a savings of $83.5 billion. These findings are published in the Journal of the American Medical Association.
“International reference pricing could yield considerable savings in the U.S.,” said Andrew Mulcahy, lead author of the study and a senior health policy researcher at RAND, a nonprofit, nonpartisan research organization.
High prescription drug prices have important implications for the American health care system, driving up overall costs, burdening some patients with high co-pays and causing many people to forgo needed medications.
Prices for brand-name drugs are higher in the U.S. compared to other high-income countries, most of which regulate drug prices.
However, inconsistent availability of data on U.S. net prices (the prices insurers pay after rebates and other discounts) complicates international comparisons of brand-name drug prices.
Researchers compared what 2020 spending would have been if the U.S. bought insulins and 50 top single-source, brand-name drugs at U.S. manufacturer prices, U.S. net prices after rebates, and at H.R. 3 international ceiling prices.
Advertisement
Spending at international rather than U.S. net prices would have reduced spending by 53.7% for oncology drugs. For insulins, spending at international prices would have still lowered spending by 44.4%.
Advertisement
Those issues include incentives for research and development, industry launch and pricing strategies, and demand responses to lower prices.
Source-Medindia